
Vitiligo

Podcasts
All News
Advertisement

Misconceptions about vitiligo, including contagion and supernatural causation, remain prevalent in many regions and are linked to increased stigma.

In a striking finding, 97% of patients who had experienced no facial repigmentation whatsoever at week 24 demonstrated measurable F-VASI improvement after 104 weeks of continuous ruxolitinib cream use.
Advertisement
Advertisement
Trending on Dermatology Times
1
Taltz Plus Zepbound Show Durable Year-One Efficacy in Psoriatic Disease
2
Dermatology Times Monthly FDA & Pipeline Review: August 2026
3
Dermatology Times August 2026 Print Recap
4
FDA Approves Brepocitinib for Dermatomyositis
5
























